Brief: Revive Therapeutics Announces Submission Of Amended Phase 3 Covid-19 Study Protocol To FDA
14/09/2022 11:01
Sept 14 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES SUBMISSION OF AMENDED PHASE
3
COVID-19 STUDY PROTOCOL TO FDA
* REVIVE THERAPEUTICS LTD - NOW SUBMITTED TO FDA A REVISED
PROTOCOL FOR FURTHER DISCUSSION AND AGREEMENT ADDRESSING A NEW
PRIMARY EFFICACY ENDPOINT
* REVIVE THERAPEUTICS LTD - PROPOSED ENDPOINTS ADDRESS SHIFT
IN
COVID-19 CLINICAL OUTCOMES OBSERVED OVER COURSE OF PANDEMIC
Source text for Eikon: ID:nGNX1P5wlZ
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure